Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Alternative Names: 5HT6 compounds; SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class Antiparkinsonians; Antipsychotics; Carbazoles; Indoles; Neuroprotectants; Obesity therapies; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Parkinson's disease; Schizophrenia
  • No development reported Obesity

Most Recent Events

  • 21 Nov 2017 Preclinical development is ongoing in Neurodegenerative disorders (Suven Life Sciences Pipeline; 9227279)
  • 16 Nov 2017 Suven Life Sciences has patent protection for selective serotonin (H3 and 5-HT6) compounds for neurodegenerative disorders in USA, Hong Kong and India
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top